(Q33576123)

28 July 2017

title

Economic evaluations of drug therapy: attitudes of primary care prescribing advisers in Great Britain (English)

1 reference

28 July 2017

T Walley

1

1 reference

28 July 2017

S Barton

series ordinal

2

1 reference

28 July 2017

J Cooke

series ordinal

3

1 reference

28 July 2017

M Drummond

series ordinal

4

1 reference

28 July 2017

publication date

1 July 1997

1 reference

28 July 2017

1 reference

28 July 2017

volume

41

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

61-72

1 reference

Current prescribing in primary care in the UK. Effects of the indicative prescribing scheme and GP fundholding

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Alterations in prescribing by general practitioner fundholders: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

FHSA medical advisers: friends or foes?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Health economics in primary care in the UK: containment of drug costs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Transferring the costs of expensive treatments from secondary to primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Is there a need for an independent centre for pharmacoeconomics in the UK?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

Promoting cost effective prescribing

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2897%2900013-4

7 January 2021

10.1016/S0168-8510(97)00013-4

Identifiers

DOI

1 reference

28 July 2017

1 reference